Anti-tumoral Effect of a Cell Penetrating and Interfering Peptide Targeting PP2A/SET Interaction

Archive ouverte

Andrini, Laura | Marin, Gustavo, H | Inda, Ana, Maria | Bruzzoni-Giovanelli, Heriberto | Garcia, Marcela | Errecalde, Jorge | Rebollo, Angelita

Edité par CCSD ; Versita -

International audience. Objective: To test cell penetrating and interfering peptide Mut3DPT-PP2A/SET in interaction between serine threonine phosphatase PP2A and its physiological inhibitor, the oncoprotein SET.Materials and methods: Adult male C3H/S-strain mice, 60 days old, were given a graft of breast adenocarcinoma cells (TN60) into subcutaneous tissue. Mut3DPT-PP2A/SET peptide was used to block PP2A and SET oncoprotein interaction. The graft-bearing animals were divided into a control group (injected with saline buffer), and an intervention group injected intraperitoneally with Mut3DPT-PP2A/SET peptide (5 mg/kg) every day from day 5 to day 37. The variables we used to compare the outcome in both groups were tumor size in mm (length×width) and histological changes. In the statistical analysis we used ANOVA and Student-Keuls multiple comparisons test and Tuckey for the post-test analysis.Results: 48 mice were grafted at day 0 with breast UNLP-C3H/S tumor cells, and after randomization, they were assigned to one of the two study groups. At day 5 all mice were injected either with placebo or with the peptide. The treated group showed significant tumor reduction (p<0.07). Histological changes showed presence of apoptosis and necrosis of tumor in treated group.Conclusion: The peptide Mut3DPT-PP2A/SET has demonstrated anti-tumor activity by reduction in vivo of tumor growth becoming a promising future in anticancer therapy.

Suggestions

Du même auteur

New Therapeutic Approach for Targeting Hippo Signalling Pathway

Archive ouverte | Dominguez-Berrocal, Leticia | CCSD

International audience

Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden

Archive ouverte | Marin, Gustavo, H | CCSD

International audience. Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illnes...

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

Archive ouverte | Bruzzoni-Giovanelli, Heriberto | CCSD

International audience. The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance o...

Chargement des enrichissements...